Sign in

Kevin Timken

Director at UTMD
Board

About Kevin Timken

Kevin C. Timken is an independent director appointed to UTMD’s Board on October 31, 2025, after retiring from a 25-year legal career advising UTMD on SEC matters. He was Partner and Co-Leader of Securities and Capital Markets at Michael Best & Friedrich, LLP (2017–2025) and a Partner at Kruse Land Maycock & Ricks, LLC (2000–2017). He holds a J.D. from the University of Utah College of Law (1997) and a B.A. cum laude in English from the University of Northern Colorado (1987) .

Past Roles

OrganizationRoleTenureCommittees/Impact
Michael Best & Friedrich, LLPPartner; Co-Leader, Securities & Capital Markets2017–2025Advised UTMD on SEC matters, providing deep governance and disclosure expertise
Kruse Land Maycock & Ricks, LLCPartner2000–2017Advised UTMD on SEC matters; long-term familiarity with UTMD’s regulatory posture
Utah Medical Products, Inc. (outside counsel)Outside Legal Counsel (advisor)~2000–2025Multi-decade advisory relationship on SEC matters; strong context for Audit and Compensation work

External Roles

OrganizationRolePublic Company?TenureNotes
Not disclosedNo other public company directorships disclosed in appointment materials

Board Governance

  • Committee assignments: Audit Committee member; Compensation and Benefits Committee member .
  • Chair roles: None disclosed for Timken; Audit Chair and Board-designated Financial Expert is Ernst G. Hoyer .
  • Board leadership and independence context: CEO is also Chair (Kevin L. Cornwell); lead independent director is Ernst G. Hoyer . Prior to the 2024/2025 transition, independent directors comprised the majority of the board .
  • Board meeting cadence and attendance: In 2024 the Board held three formal meetings; all directors attended applicable meetings during incumbency; independent directors also met in executive session four times . Timken joined on Oct 31, 2025; specific attendance data for him is not yet disclosed .

Fixed Compensation

ComponentAmountTiming/Notes
Standard Board member cash retainer$7,650 per quarter Pro-rated for Q4’25 due to October 31 appointment
Annualized outside director cash retainer (2025 policy)$30,600 Policy rate for 2025 outside directors
Committee chair fees (policy)$4,200 for Audit Chair; $4,200 for Executive Committee outside member Timken is not disclosed as a chair; these fees indicate governance pay structure
Meeting feesNot disclosedNo per-meeting fees disclosed in proxy/8-K

Performance Compensation

Award TypeGrant DateShares/UnitsExercise/Grant PriceVestingTerm/Other
Non-qualified stock optionsOct 31, 202510,000$58.10 per share Vests over 4 years, contingent on continued Board service Term not disclosed in 8-K; award under Board member arrangements

Performance Metric Table (for director pay)

MetricTargetActual/StructureApplicability
Performance metrics tied to director compensationNot disclosedUTMD’s detailed performance metrics apply to executive/employee MB plan (e.g., EBITDA, EPS, ROE), not to routine director pay Not applicable to director compensation

Other Directorships & Interlocks

CompanyRoleInterlock/RelationshipNotes
None disclosedAppointment disclosures contain no other public company boards or interlocks

Expertise & Qualifications

  • Securities law and capital markets specialist with 25 years advising UTMD on SEC compliance; immediately additive to Audit and Compensation governance .
  • J.D. (University of Utah) and prior partner leadership roles; enhances oversight of disclosure controls and executive pay structures .
  • Familiarity with UTMD’s risk oversight and governance framework via prior advisory role .

Equity Ownership

CategoryShares/OptionsStatusNotes
Common shares beneficially ownedNot disclosedNo Form 3/Proxy entry available for Timken due to late-2025 appointment timing
Options granted (director)10,000Unvested; 4-year vestingStrike price $58.10; granted on appointment
Shares pledged as collateralNot disclosedNo pledging disclosure for Timken in appointment materials
Change-in-control treatment (plan-wide)In-the-money value paid to optionees upon change of controlPlan-wide policyUTMD policy pays appreciation above exercise price to all optionees on change of control

Say-on-Pay & Shareholder Feedback (2025 Annual Meeting)

ProposalForAgainstAbstentionsBroker Non-Votes
Advisory vote on executive compensation2,383,762 39,327 4,985 732,568
Auditor ratification (Haynie & Co.)3,148,121 10,548 1,973
Director election (Carrie Leigh)665,574 For; 1,762,500 Withheld 732,568

Insider Trades

  • Insider-trades check: No Form 4 transactions found for “Timken” in UTMD between 2025-10-01 and 2025-11-20 (post-appointment window), suggesting no immediate open-market trades or additional grants beyond the disclosed option award in the 8-K.

Governance Assessment

  • Strengths: Timken’s securities law expertise is well-aligned with Audit Committee needs and compensation oversight, likely improving disclosure rigor and pay governance. His appointment expands the Board to six, potentially improving committee bandwidth .
  • Alignment: Director compensation is modest (annualized $30,600 cash retainer) and supplemented with multi-year vesting stock options, aligning incentives with long-term shareholder value .
  • Independence and potential conflicts: Timken served as UTMD’s outside counsel for over 20 years, which enhances institutional knowledge but may raise perceived independence concerns; no related-party transactions are disclosed for 2024 in the latest proxy (“None”), but this predates his appointment . Monitoring for any continuing financial ties to prior firms is prudent.
  • Attendance/engagement: The Board reported full attendance for 2024, but Timken’s attendance is not yet disclosed given his late-2025 appointment; future proxy disclosure will be informative .
  • RED FLAGS: Potential independence optics due to prior legal advisory relationship; ensure clear recusal protocols for any matters involving prior engagements, and verify absence of ongoing fee arrangements or third-party payments for board service (company states none) .

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%